Amanote Research
Register
Sign In
Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients
Hematological Oncology
- United Kingdom
doi 10.1002/hon.28_2629
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
W.Q. Zhang
B. Hu
L. Jin
J. Yang
J. Du
S. Wang
Y.L. Ren
Y. Liu
Y.H. Zhang
Publisher
Wiley
Related search
Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
International Journal of Molecular Sciences
Organic Chemistry
Molecular Biology
Theoretical Chemistry
Inorganic Chemistry
Computer Science Applications
Spectroscopy
Medicine
Catalysis
Physical
Chimeric Antigen Receptor T Cells for the Treatment of Lymphoma
Annals of Lymphoma
Chimeric Antigen Receptor T-Cells
Cancer Journal
Cancer Research
Oncology
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Older, Vulnerable Patients With Relapsed/Refractory Large B-Cell Lymphoma
Haematologica
Hematology
Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Frontiers in Oncology
Cancer Research
Oncology
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial
The Lancet
Medicine
